BREAST CANCER METASTATIC

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This early-stage trial tests the safety of combining two drugs, olaparib and vorinostat, in people with advanced breast cancer that has returned or spread. About 28 participants will receive the combination to find the best dose and check for side effects. The goal is to see if t…

This phase 2 trial tests the safety and effectiveness of combining sacituzumab govitecan (Trodelvy) with trastuzumab (Herceptin) in 28 people with HER2+ metastatic breast cancer that has worsened after treatment with trastuzumab deruxtecan. The goal is to see how many participant…

This study has two parts. First, it screens people with HR+ HER2-low metastatic breast cancer who are on standard CDK4/6 inhibitor therapy to find those with lingering tumor DNA in their blood—a sign of high relapse risk. Then, those high-risk patients receive the drug trastuzuma…

This study is for people with HER2-positive metastatic breast cancer who have had a lasting response (complete or partial remission for over 2 years) on anti-HER2 therapy. Researchers will use a personalized blood test called Signatera to look for tiny amounts of cancer DNA. The …

This study looks at whether simple blood tests can tell if a woman's metastatic breast cancer is stable, so she can skip some routine scans. About 97 women with ER-positive/HER2-negative cancer will give blood samples at each scan visit. The goal is to create a smart algorithm th…

This was an observational study designed to collect medical data from people with HR+/HER2- advanced breast cancer during routine care. The goal was to track treatment effectiveness and side effects in real-world settings. However, the study was withdrawn before enrolling any par…